Literature DB >> 24463697

Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.

Ying Ding1, Sheng-Xiang Rao, Tao Meng, Caizhong Chen, Renchen Li, Meng-Su Zeng.   

Abstract

OBJECTIVES: This study evaluates the value of Gd-EOB-DTPA-enhanced MRI for diagnosis and staging of non-alcoholic fatty liver disease (NAFLD) in an animal model by T1 relaxation time measurement.
METHODS: Thirty-four rabbits were divided into the control group (n = 10) and NAFLD group, which was split into four groups (n = 6) with a high-fat diet for an interval of 3 weeks. A dual flip angle was performed before and at the hepatobiliary phase (HBP). T1 relaxation times of the liver parenchyma and the decrease rate (∆%) were calculated. Histological findings according to semi-quantitative scoring of steatosis, activity and fibrosis were the standard of reference.
RESULTS: HBP and ∆% T1 relaxation time measurement showed significant differences between normal and NAFLD groups, between non-alcoholic steatohepatitis (NASH) and NAFLD without NASH (p = 0.000-0.049), between fibrosis groups (p = 0.000-0.019), but no difference between F1 and F2 (p = 0.834). The areas under the receiver operating characteristic curves (AUCs) of T1 relaxation time for HBP and ∆% were 0.86-0.93 for the selection of NASH and activity score ≥2, and 0.86-0.95 for the selection of F ≥ 1, 2, 3. No significant difference was found for diagnostic performance between HBP and ∆% T1 relaxation time.
CONCLUSIONS: HBP T1 relaxation time measurement of Gd-EOB-DTPA-enhanced MRI was useful to evaluate NAFLD according to the SAF score. HBP T1 relaxation time measurement was as accurate as ∆% T1 relaxation time. KEY POINTS: • Gd-EOB-DTPA-enhanced MRI could give useful information on NAFLD. •HBP T 1 relaxation time measurement was useful for the evaluation of NAFLD. • HBP T 1 relaxation time measurement was as accurate as ∆%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24463697     DOI: 10.1007/s00330-014-3096-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

1.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.

Authors:  O Dahlqvist Leinhard; N Dahlström; J Kihlberg; P Sandström; T B Brismar; O Smedby; P Lundberg
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

3.  The Possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans.

Authors:  Akinaga Sonoda; Norihisa Nitta; Shinich Ohta; Ayumi Nitta-Seko; Keiko Tsuchiya; Yukihiro Nagatani; Kenichi Mukaisho; Masashi Takahashi; Kiyoshi Murata
Journal:  Acad Radiol       Date:  2011-01-14       Impact factor: 3.173

Review 4.  Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Authors:  Luca Miele; Alessandra Forgione; Giovanni Gasbarrini; Antonio Grieco
Journal:  Transl Res       Date:  2007-03       Impact factor: 7.012

5.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

6.  Population-based risk factors and resource utilization for HCC: US perspective.

Authors:  A Sanyal; A Poklepovic; E Moyneur; V Barghout
Journal:  Curr Med Res Opin       Date:  2010-09       Impact factor: 2.580

Review 7.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

Authors:  Nina F Schwenzer; Fabian Springer; Christina Schraml; Norbert Stefan; Jürgen Machann; Fritz Schick
Journal:  J Hepatol       Date:  2009-06-11       Impact factor: 25.083

8.  Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; Ronald P J Oude Elferink; David G Besselsen; Robert P Erickson; Nathan J Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-07       Impact factor: 4.432

9.  Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents.

Authors:  L Pascolo; F Cupelli; P L Anelli; V Lorusso; M Visigalli; F Uggeri; C Tiribelli
Journal:  Biochem Biophys Res Commun       Date:  1999-04-21       Impact factor: 3.575

Review 10.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

Authors:  Christoph J Zech; Karin A Herrmann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

View more
  18 in total

1.  Gd-EOB-DTPA-enhanced MRI T1 mapping for assessment of liver function in rabbit fibrosis model: comparison of hepatobiliary phase images obtained at 10 and 20 min.

Authors:  Zhi-Peng Zhou; Li-Ling Long; Li-Juan Huang; Teng-Fei Yang; Zhong-Kui Huang
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

2.  Influence of fat deposition on T1 mapping of the pancreas: evaluation by dual-flip-angle MR imaging with and without fat suppression.

Authors:  Mayumi Higashi; Masahiro Tanabe; Munemasa Okada; Matakazu Furukawa; Etsushi Iida; Katsuyoshi Ito
Journal:  Radiol Med       Date:  2019-09-27       Impact factor: 3.469

3.  Quantitative assessment of disease severity of primary sclerosing cholangitis with T1 mapping and extracellular volume imaging.

Authors:  Sehnaz Evrimler; Jordan K Swensson; Vijay S Are; Temel Tirkes; Raj Vuppalanchi; Fatih Akisik
Journal:  Abdom Radiol (NY)       Date:  2020-11-01

4.  Assessing liver function in patients with HBV-related HCC: a comparison of T₁ mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI.

Authors:  Ying Ding; Sheng-Xiang Rao; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-12-19       Impact factor: 5.315

5.  Evaluation of liver function in patients with chronic hepatitis B using Gd-EOB-DTPA-enhanced T1 mapping at different acquisition time points: a feasibility study.

Authors:  Jiamin Li; Boling Cao; Xinjun Bi; Weipeng Chen; Lanjing Wang; Zhongli Du; Xueqin Zhang; Xiangrong Yu
Journal:  Radiol Med       Date:  2021-06-08       Impact factor: 3.469

6.  Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography.

Authors:  Constanze Bardach; Leonie Morski; Katharina Mascherbauer; Carolina Donà; Matthias Koschutnik; Kseniya Halavina; Christian Nitsche; Dietrich Beitzke; Christian Loewe; Elisabeth Waldmann; Michael Trauner; Julia Mascherbauer; Christian Hengstenberg; Andreas Kammerlander
Journal:  J Clin Med       Date:  2022-05-19       Impact factor: 4.964

Review 7.  Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.

Authors:  Jérémy Dana; Aïna Venkatasamy; Antonio Saviano; Joachim Lupberger; Yujin Hoshida; Valérie Vilgrain; Pierre Nahon; Caroline Reinhold; Benoit Gallix; Thomas F Baumert
Journal:  Hepatol Int       Date:  2022-02-09       Impact factor: 9.029

8.  Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yoshiki Asayama; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Ken Shirabe; Tomoharu Yoshizumi; Kazuhiro Kotoh; Norihiro Furusyo; Tomoyuki Hida; Yoshinao Oda; Taisuke Fujioka; Hiroshi Honda
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

9.  Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma.

Authors:  Shuai Wang; Junheng Li; Diru Zhu; Ting Hua; Binghui Zhao
Journal:  Quant Imaging Med Surg       Date:  2020-05

10.  Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma.

Authors:  Zhenpeng Peng; Mengjie Jiang; Huasong Cai; Tao Chan; Zhi Dong; Yanji Luo; Zi-Ping Li; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2016-08-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.